During the diagnostic pathway, in patients with no smoking history, genomic profiling is prioritised, which may hinder tumour subtyping or less relevant marker testing such as PDL1; never-smokers are offered chemo-immunotherapy regardless of the PDL1 levels [46]. The gene discussed is CD274; the disease is neoplasm.